It is crucial to remove an additional cardiac toxicity risk factor and promptly detect left ventricular dysfunction during treatment with BRAF/MEK inhibitors since it often results in discontinuation of the oncological therapy and, while most of the cardiac side effects could be adequately managed and are reversible with the interruption of treatment, fatal events considered to be due to arrhythmias or sudden cardiac death may occur. The gene discussed is BRAF; the disease is cardiac arrhythmia.